Oligonucleotide p53 Down-Regulation for CKD Progression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods are inadequate for effectively preventing or delaying the progression of chronic kidney disease (CKD) and exacerbating its progression, particularly in response to recurring renal insults, which often lead to acute kidney injury (AKI) and subsequent kidney damage.
Innovation Solution
Administration of an oligonucleotide compound that down-regulates the expression of the p53 gene, specifically using chemically modified siRNA, within 24 hours of renal insult to inhibit kidney damage and progression of CKD, targeting genes associated with renal ischemia and injury.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatment methods are used for chronic kidney disease, then treatment simplicity is maintained, but the effectiveness in preventing or delaying CKD progression is insufficient
Solution Approach 1:
The patent applies preliminary action by administering the oligonucleotide compound within 24 hours of renal insult to prevent kidney damage before it fully develops. This early intervention down-regulates p53 expression proactively, preventing the cascade of cellular damage that would otherwise lead to AKI and subsequent CKD progression, thereby resolving the contradiction between treatment effectiveness and complexity.
Solution Approach 2:
The patent employs parameter changes by specifically targeting and down-regulating the expression level of the p53 gene through oligonucleotide administration. By changing the molecular parameter of p53 expression levels in the kidney, the treatment achieves protective effects against renal ischemia and injury, improving CKD prevention effectiveness without requiring complex multi-target interventions.
2Reliability
If oligonucleotide compound is administered within 24 hours of renal insult, then kidney damage is attenuated, but treatment timing precision requirements increase
Solution Approach 1:
The patent implements preliminary action by establishing a clear 24-hour administration window that begins before renal insult fully manifests. This allows clinicians to intervene early in the pathological process, down-regulating p53 expression before irreversible kidney damage occurs, thereby achieving reliable protection while providing a defined (though precise) timing framework.
3Reliability
If p53 gene expression is down-regulated to protect renal cells, then ischemic injury is prevented, but potential off-target effects may increase
Solution Approach 1:
The patent applies local quality by using chemically modified siRNA oligonucleotides that are designed to target p53 expression specifically in renal tissue. The chemical modifications enhance local stability and specificity in the kidney, ensuring that p53 down-regulation occurs primarily where needed (in renal cells subjected to ischemic insult) rather than systemically, thereby reducing potential off-target effects while maintaining protective benefits.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The oligonucleotide compound effectively attenuates kidney damage and prevents the progression of CKD by reducing the expression of p53, thereby protecting renal cells from ischemic injury and minimizing proteinuria and GFR decline.
Implementation Method 1
Administration of an oligonucleotide compound that down-regulates the expression of the p53 gene, specifically using chemically modified siRNA
Data Source
Figure 1
Figure 2~3
Figure 4
AI summary
The present invention relates to oligonucleotide compounds for use in methods for treating chronic kidney disease (CKD) including methods for preventing or delaying onset of CKD and methods for preventing exacerbation and progression of CKD. In particular embodiments, the invention provides methods for treating a subject at risk of developing CKD comprising administering to the subject a composition comprising a) a therapeutically effective amount of at least one oligonucleotide compound which inhibits the expression of a human target gene associated with the kidney disease chosen from p53 and CASP2; and b) a pharmaceutically acceptable excipient or carrier, or mixtures thereof, thereby reducing the risk of CKD in the subject.